Sanofi's chief medical officer Dietmar Berger has previously said that lead-212 has a "differentiated biophysical and clinical profile, reinforcing its potential to be a transformative radioligand ...

Sanofi ends development of CEACAM5-targeting ADC tusamitamab ravtansine after it fails a phase 3 trial in non-small cell lung cancer (NSCLC) ...

Get the latest news and real-time alerts from Gilead Sciences, Inc. (GILD) stock at Seeking Alpha.